Key Elements of a Life Sciences SPAC

Registration is now closed. Please email alicia@onenucleus.com to be added to the waitlist.

In association with

Context:

The increasing interest in the Special Purpose Acquisition Company (SPAC) in Life Sciences, accelerated perhaps by the disruption and market dynamics created by Covid-19, is evident. The attraction of SPACs in principle to investors and Life Science companies is on the surface very clear. More stable, reduced risk, less burdensome and potentially more rapid route to an IPO. There may also be benefits in terms of valuation and pricing certainty. The importance on its ESG factors could be critical to success so this session will discuss the key considerations when creating and operating a SPAC such as the pros and cons, legal framework, leadership and governance, investment bank and market engagement and the IPO.

Agenda:

16.00  Welcome

          Tony Jones, CEO, One Nucleus

16.05  Introductory remarks from the chair

          Christos Farmakis, Director of Corporate Finance, BBCSL

16.15  Perspectives on a Life Science SPAC:

             - The Legal Framework

               Robert Fenner, Partner, Taylor Wessing

             - Building the Team

               Paul Harvey, Client Support Director, Seven Life Sciences

             - The Investment Structure
                Silvia Barettini, Relationship Manager, Europe, I-Bankers Securities, Inc

             - Assessing the Risk
               David Garrigus, Executive Vice President, Management Liability & SPAC Leader, HUB International

17.05  Open Q&A

17.30  Close  

Registration: Free to attend and open to all